Endocrine oncology

Parity as a Risk Factor for Differentiated Thyroid Carcinoma: A Population-based Study

J Clin Endocrinol MetabPublished Population-based case-control study

Authors' conclusion

High parity, primarily among Arab women, was associated with increased DTC risk, with significance observed at 4 or more deliveries.

Study context

Population
Women in a high-multiparity population, single tertiary medical center, 1982–2022; median age at differentiated thyroid carcinoma (DTC) diagnosis 39 years; 60% Jewish, 40% Arab
Participants
300 vs 900
Comparison
Parity and DTC risk; DTC cases vs controls
  • DTCn = 300
  • Controlsn = 900reference
Outcome
Association between parity (number of deliveries before DTC diagnosis) and DTC risk, logistic regression adjusted for socioeconomic status, TSH, oral contraceptive use and autoimmune thyroid diseases
Methodological detailsmatched by birth year and ethnicity, single tertiary medical center
  • Matched by birth year and ethnicity
  • Single tertiary medical center

Main finding

As reported in the abstract

DTC risk by number of deliveries

4 deliveries: OR

1.70

95% CI 1.051–2.741P = .030

6 or more deliveries: OR

1.89

95% CI 1.052–3.393P = .033

Observational data: associations, not effects.

Further findings

OutcomeP value
Hashimoto thyroiditis (baseline)Higher rate in casesP < 0.001
Graves' disease (baseline)Higher rate in casesP = 0.005

Hashimoto thyroiditis (baseline)

Higher rate of Hashimoto thyroiditis in cases

Graves' disease (baseline)

Higher rate of Graves' disease in cases

Parity–DTC association by ethnicity

Association largely driven by Arab women, who had significantly higher grand multiparity rates (P < .001)

Original publication

Parity as a Risk Factor for Differentiated Thyroid Carcinoma: A Population-based Study. J Clin Endocrinol Metab. Published 24 November 2025. doi:10.1210/clinem/dgaf642

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.